Clinical trials: High-Risk Cancer, open to volunteers
AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")
This phase I trial studies the safety and side effects of glofitamab plus a chemoimmunotherapy regimen called R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in treating patients newly-diagnosed…
- Conditions
- AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT07649304
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
This phase I/II trial studies the side effects and best dose of gilteritinib and to see how well it works in combination with azacitidine and venetoclax in treating patients with FLT3-mutation positive acute myeloid leukemia…
- Conditions
- Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia
- Trial name
- NCT04140487
- Testing
- Azacitidine, Gilteritinib, Venetoclax
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- M.D. Anderson Cancer Center
Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy.
- Conditions
- Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
- Trial name
- NCT07225439
- Testing
- Allogeneic NK cells, Rituximab, Tafasitamab
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Paolo Caimi, MD
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid…
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
- Trial name
- NCT05554406
- Testing
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 227 sites in United States, Canada and 1 more
- Volunteers
- 335 people
- Sponsor
- National Cancer Institute (NCI)
Pregnancy Related, Pregnancy Complications
Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
The Relugolix Pregnancy Registry is a prospective, observational cohort study designed to evaluate the association between relugolix-containing therapy exposure during pregnancy and subsequent maternal, fetal, and infant…
- Conditions
- Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk
- Trial name
- NCT05739123
- Testing
- Relugolix-Containing Product
- Where
- United States
- Volunteers
- 728 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
Early Hormone Receptor-positive Breast Cancer
Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy
A prospective, randomized, comparative study to evaluate efficacy of anticancer chemotherapy in predicting prognosis and determining chemotherapy method in early Hormone Receptor-positive breast cancer patients with…
- Trial name
- NCT04278469
- Testing
- Chemotherapy Drugs, Cancer
- Where
- South Korea
- Volunteers
- 194 people
- Sponsor
- Gencurix, Inc.
Neuroblastoma, GD2 Antibody
A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma
This is a prospective, single-arm, open, single-center clinical trial to evaluate the safety and efficacy of autologous NK cells combined with chemotherapy and GD2 monoclonal antibody in the treatment of newly diagnosed high-risk…
- Conditions
- Neuroblastoma, GD2 Antibody, Autologous NK Cell
- Trial name
- NCT06948994
- Testing
- autologous NK cell plus GD2 antibody
- Volunteers
- 15 people
- Sponsor
- Guangzhou Women and Children's Medical Center
Gastric Cancer, Chemotherapy, Adjuvant
The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.
The goal of this randomized clinical trial is to investigate whether pressurized intraperitoneal chemotherapy (PIPAC), delivered immediately after minimally invasive D2 gastrectomy and repeated 6-8 weeks later, improves 12-month…
- Conditions
- Gastric Cancer, Chemotherapy, Adjuvant, Peritoneal Metastases, Minimally Invasive Surgical Procedures
- Trial name
- EPICURE (NCT06295094)
- Testing
- Cisplatin, Doxorubicin
- Where
- 5 sites in United States, Denmark and 3 more
- Volunteers
- 264 people
- Sponsor
- Odense University Hospital
Ovarian Cancer, Fallopian Tube Cancer
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
- Trial name
- NCT06906341
- Testing
- Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg
- Where
- 49 sites in United States, Belgium and 6 more
- Volunteers
- 270 people
- Sponsor
- Corcept Therapeutics
Glioma
Protoporphyrin Imaging in Multispectral Evaluation of Resections
Observational non-interventional investigation to evaluate the potential of multispectral imaging in improving tumor visualization.
- Trial name
- PRIMER (NCT07021573)
- Testing
- KINEVO 900 S with BLUE 400
- Where
- 10 sites in Austria, Germany and 1 more
- Volunteers
- 80 people
- Sponsor
- Medical University Innsbruck
Prostate Cancer (Adenocarcinoma)
Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
This is a Phase I/II trial evaluating the effectiveness of adding neoadjuvant HDR-B prior to RALP for HR-PCa patients with selective AAB for decipher high risk or pathologically node positive patients.
- Trial name
- NCT07182279
- Testing
- Brachytherapy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- The Methodist Hospital Research Institute
HIV (Human Immunodeficiency Virus), AIDS
Disease Evolution and Risk Factors of AIDS-related Prevalent Cancers
This study aims to investigate the disease progression trends and risk factors of common AIDS-related tumors, including Kaposi sarcoma, lymphoma, lung cancer, and et al., among people living with HIV.
- Conditions
- HIV (Human Immunodeficiency Virus), AIDS, Kaposi Sarcoma (KS), Lymphoma
- Trial name
- NCT07696169
- Volunteers
- 1,000 people
- Sponsor
- Shenzhen Third People's Hospital
Ovarian Cancer
Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients
A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered by the intraperitoneal route to identify a dose that is…
- Trial name
- OCTOPOD-IP (NCT07211659)
- Testing
- THEO-260
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Theolytics Limited
Uterine Cervical Neoplasms
Comparison of Conventional and Hypofractionated IMRT in High-Risk Cervical Cancer Post-Radical Hysterectomy
Radical hysterectomy and radiation therapy are standard treatments for cervical cancer. However, there are no reported studies on the frequency of side effects and treatment outcomes when hypofractionated radiation therapy and…
- Trial name
- POHIM-P3 (NCT06509724)
- Testing
- Conventional Fractionated IMRT, Hypofractionated IMRT
- Where
- South Korea
- Volunteers
- 248 people
- Sponsor
- Samsung Medical Center
Myelodysplastic Neoplasms, Transplantation
Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes
A Single-Arm, Prospective Clinical Study of Venetoclax Combined with Azacitidine Followed by Bridging Transplantation in Patients with High-Risk Myelodysplastic Neoplasms with Increased Blasts 2 (MDS-IB2)
- Trial name
- NCT07047183
- Testing
- VEN (Venetoclax)
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Yehui Tan
High-risk Prostate Cancer, PSMA PET
Serial PSMA PET for Therapy Monitoring in Clinically Significant Prostate Cancer
This prospective, multicenter study aims to evaluate the clinical utility of serial PSMA PET for therapy monitoring in patients with newly diagnosed clinically significant prostate cancer.
- Conditions
- High-risk Prostate Cancer, PSMA PET, Treatment Response, Therapy Monitoring
- Trial name
- PSMA-TM (NCT07553780)
- Where
- 9 sites in China
- Volunteers
- 110 people
- Sponsor
- Xijing Hospital
Rectal Cancer
A Phase II Prospective Study of Maastro Applicator Brachytherapy for Rectal Cancer
Rectal cancer is a common type of cancer and an important cause of illness and death worldwide. In 2020, cancers of the colon and rectum were the fourth most common cancers globally, and about one third of these cases were rectal…
- Trial name
- NCT07402486
- Testing
- Rectal HDR brachytherapy via Maastro Applicator
- Volunteers
- 20 people
- Sponsor
- Siriraj Hospital
Locally Advanced and Metastatic Prostate Cancer
Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer
Prostate cancer is the most common non-skin cancer diagnosed among men and the second leading cause of male cancer deaths in the United States. In 2013, it is estimated that 29,270 men have died from prostate cancer.
- Trial name
- NCT02971358
- Testing
- Radical prostatectomy
- Where
- Austria
- Volunteers
- 200 people
- Sponsor
- Medical University of Vienna
Cancer Colorectal
ctDNA Methylation Application in Postoperative Relapse and Adjuvant Chemotherapy Efficacy Evaluation
In this study, the investigators aimed to apply their previously developed multi-locus blood-based assay targeting circulating tumor DNA methylation to monitor postoperative relapse and evaluate adjuvant chemotherapy efficacy in…
- Trial name
- NCT05536089
- Testing
- a multi-locus blood-based assay
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Singlera Genomics Inc.
Bladder (Urothelial, Transitional Cell) Cancer, NMIBC
DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC
The purpose of this study is to learn about the safety and effects of the study medicine (Disitamab Vedotin) in people with non-muscle invasive bladder cancer.
- Trial name
- HERO (NCT07207824)
- Testing
- Active Comparator: BCG induction and maintenance, DV + BCG induction and maintenance
- Where
- China
- Volunteers
- 182 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.